Bafetinib
| Code | Size | Price |
|---|
| SYN-1179-M100 | 100 mg | Enquire |
Quantity:
| SYN-1179-M001 | 1 mg | £127.00 |
Quantity:
| SYN-1179-M005 | 5 mg | £209.00 |
Quantity:
| SYN-1179-M010 | 10 mg | £373.00 |
Quantity:
| SYN-1179-M050 | 50 mg | £1,111.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
NS-187; INNO-406
Appearance:
Solid.
CAS:
859212-16-1
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07
Hazards:
H303, H317, H333
InChi:
InChI=1S/C30H31F3N8O/c1-19-4-7-23(13-27(19)39-29-36-10-8-26(38-29)22-14-34-18-35-15-22)37-28(42)20-5-6-21(25(12-20)30(31,32)33)16-41-11-9-24(17-41)40(2)3/h4-8,10,12-15,18,24H,9,11,16-17H2,1-3H3,(H,37,42)(H,36,38,39)/t24-/m0/s1
InChiKey:
ZGBAJMQHJDFTQJ-DEOSSOPVSA-N
Long Description:
Chemical. CAS: 859212-16-1. Formula: C30H31F3N8O. MW: 576.6. Bafetinib (INNO-406) is a potent and selective dual Bcr-Abl, Lyn inhibitor with IC(50) values of 5.8nM and 19nM, respectively.
Molecular Formula:
C30H31F3N8O
Molecular Weight:
576.6
Package Type:
Plastic Vial
Precautions:
P261, P272, P280, P302, P352, P333, P313, P321, P363, P501
Product Description:
Bafetinib (INNO-406) is a potent and selective dual Bcr-Abl, Lyn inhibitor with IC(50) values of 5.8nM and 19nM, respectively.
Purity:
>95%
Signal word:
Warning
Solubility Chemicals:
Soluble in DMSO. Slightly soluble (<1mg/ml) in ethanol.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia: S. Kimura, et al.; Blood 106, 3948 (2005)
Related Products
| Product Name | Product Code | Supplier | Genistein | AG-CN2-0427 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|